Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary FIVE PRIME THERAPEUTICS PROVIDES AN UPDATE ON ITS STRATEGIC DISCOVERY COLLABORATIONS WITH PFIZER AND GLAXOSMITHKLINE
FivePrime Concludes Strategic Collaboration with Pfizer to Discover Innovative Biologics for Oncology and Diabetes FivePrime and GlaxoSmithKline Expand Strategic Collaboration to Discover Innovative Biologics for Skeletal Muscle Disorders
Toggle Summary ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology
LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- ADC Therapeutics Sarl ('ADC Therapeutics'), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), and Five Prime

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Thursday, September 06, 2018 2:30 PM EDT
Summary Toggle Wednesday, August 08, 2018 4:30 PM EDT
Summary Toggle Thursday, June 14, 2018 8:00 AM PDT